Soleno Therapeutics, Inc. – NASDAQ:SLNO

Add to watchlist

$66.81

+21.99

+49.06%

Market closed

Open in about 7 hours

-5.98%

month

-5.98%

quarter

+13.55%

year

Market Cap	1.92B
Enterprise value	8.47M

P/E	-0.93
EV/Sales	N/A
EV/EBITDA	-0.25
Price/Sales	N/A
Price/Book	2.21
PEG ratio	-0.01
EPS	-2.67

Revenue	N/A
EBITDA	-52.10M
Income	-52.03M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Soleno Therapeutics Stock Forecast

M Q Y

Last Year

$67

Potential upside: 0.28%

Analysts Price target
Financials & Ratios estimates

Soleno Therapeutics, Inc. (NASDAQ:SLNO): Profit margin
Jun 2023	0	-8.47M
Sep 2023	0	-10.86M
Dec 2023	3.44M	-11.29M	-327.8%
Mar 2024	0	-21.39M

Soleno Therapeutics, Inc. (NASDAQ:SLNO): Debt to assets
Jun 2023	30944000	18.51M	59.84%
Sep 2023	63548000	40.32M	63.46%
Dec 2023	180691000	23.18M	12.83%
Mar 2024	168837000	25.45M	15.07%

Soleno Therapeutics, Inc. (NASDAQ:SLNO): Cash Flow
Jun 2023	-5.56M	0	17.06M
Sep 2023	-6.33M	0	39.40M
Dec 2023	-6.31M	0	123.55M
Mar 2024	-12.52M	-115.24M	938K

Soleno Therapeutics alternative data

Soleno Therapeutics, Inc. (NASDAQ:SLNO): Employee count
Aug 2023	25
Sep 2023	25
Oct 2023	25
Nov 2023	25
Dec 2023	25
Jan 2024	25
Feb 2024	25
Mar 2024	33
Apr 2024	33
May 2024	33
Jun 2024	33
Jul 2024	33

Soleno Therapeutics
Hedge Funds Holdings Q1 2023

24.45% -13.00%

of SLNO is owned by hedge funds

13 -10

hedge funds hold SLNO stock

2.05M -977.75K

shares is hold by hedge funds

SLNO hedge funds holdings changes

Soleno Therapeutics
Insider Trading

Soleno Therapeutics, Inc. (NASDAQ:SLNO): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	1116789	0
Nov 2023	0	108756
Dec 2023	0	169963
Jan 2024	0	3756
Apr 2024	0	1129833
Jul 2024	0	30786

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	1 Jul 2024	MACKANESS JAMES H officer: CHIEF FI..	Common Stock	5,622	$41.63	$234,016
Sale	1 Jul 2024	HIRANO PATRICIA C officer: SEE REMARKS officer: SEE REMARKS	Common Stock	473	$41.22	$19,498
Sale	1 Jul 2024	HIRANO PATRICIA C officer: SEE REMARKS officer: SEE REMARKS	Common Stock	1,697	$41.63	$70,638
Sale	1 Jul 2024	YEN KRISTEN officer: SEE REMARKS officer: SEE REMARKS	Common Stock	473	$41.22	$19,498
Sale	1 Jul 2024	YEN KRISTEN officer: SEE REMARKS officer: SEE REMARKS	Common Stock	1,697	$41.63	$70,638
Sale	1 Jul 2024	MACKANESS JAMES H officer: CHIEF FI..	Common Stock	1,568	$41.22	$64,636
Sale	1 Jul 2024	ANISH BHATNAGAR director, officer..	Common Stock	4,198	$41.22	$173,050
Sale	1 Jul 2024	ANISH BHATNAGAR director, officer..	Common Stock	15,058	$41.63	$626,789
Sale	30 Apr 2024	VIVO OPPORTUNITY, LLC 10 percent owner 10 percent owner	Common Stock	351,242	$45.13	$15,851,551
Sale	29 Apr 2024	VIVO OPPORTUNITY, LLC 10 percent owner 10 percent owner	Common Stock	750,000	$47.8	$35,850,000

SLNO insider trading transactions

Soleno Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Anish Bhatnagar (1970) Pres, Chief Executive Officer, Chief Operating Officer & Director	55		$756,000
Mr. James H. MacKaness (1964) Chief Financial Officer	61		$198,990

Soleno Therapeutics
Latest News

Tuesday, 17 December 2024
16:05	Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC	globenewswire.com
Wednesday, 27 November 2024
08:00	Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference	globenewswire.com
Tuesday, 26 November 2024
08:30	Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome	globenewswire.com
Thursday, 14 November 2024
16:05	Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024	globenewswire.com
Thursday, 10 October 2024
14:53	Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments	seekingalpha.com
Wednesday, 9 October 2024
10:35	SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA	zacks.com
09:50	Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's Why	zacks.com
Tuesday, 8 October 2024
18:51	SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval	gurufocus.com
18:29	Why Soleno Therapeutics Stock Blasted 9% Higher Today	fool.com
Thursday, 3 October 2024
12:03	Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc	gurufocus.com
Monday, 16 September 2024
16:05	Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference	globenewswire.com
Wednesday, 28 August 2024
11:25	Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review	zacks.com
Tuesday, 27 August 2024
13:00	Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients	seekingalpha.com
08:00	Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome	globenewswire.com
Monday, 19 August 2024
16:17	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Friday, 28 June 2024
08:00	Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome	globenewswire.com
Monday, 24 June 2024
17:18	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 11 June 2024
13:00	SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Long-Term Investors to Contact the Firm	accesswire.com
Thursday, 6 June 2024
16:18	3 Stocks That Have Seen Higher Share Gains Than Super Micro Computer	247wallst.com
Wednesday, 22 May 2024
16:05	Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024	globenewswire.com
08:00	Soleno Therapeutics to Participate in Upcoming Investor Conferences	globenewswire.com
Wednesday, 15 May 2024
08:00	Soleno Therapeutics Stands with the Prader-Willi Syndrome Community	globenewswire.com
Thursday, 9 May 2024
16:05	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	globenewswire.com
Thursday, 2 May 2024
22:32	Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock	globenewswire.com
16:01	Soleno Therapeutics Announces Proposed Public Offering of Common Stock	globenewswire.com
Tuesday, 30 April 2024
08:00	Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome	globenewswire.com
Monday, 29 April 2024
11:11	Why Soleno Therapeutics Stock Is Skyrocketing Today	The Motley Fool
Wednesday, 14 February 2024
09:51	Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why	Zacks Investment Research
Friday, 26 January 2024
09:51	Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going	Zacks Investment Research
Monday, 22 January 2024
22:42	Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families	Seeking Alpha

Ideas & Opinions

Seeking Alpha 29 Apr 2024

Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch
Seeking Alpha 23 Jan 2024

Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Seeking Alpha 26 Nov 2023

Soleno Therapeutics: Impressive Data, But Never Forget Amarin

Frequently Asked Questions (FAQ)

What's the price of Soleno Therapeutics stock today?

One share of Soleno Therapeutics stock can currently be purchased for approximately $66.81.
When is Soleno Therapeutics's next earnings date?

Unfortunately, Soleno Therapeutics's (SLNO) next earnings date is currently unknown.
Does Soleno Therapeutics pay dividends?

No, Soleno Therapeutics does not pay dividends.
How much money does Soleno Therapeutics make?

Soleno Therapeutics has a market capitalization of 1.92B.
What is Soleno Therapeutics's stock symbol?

Soleno Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SLNO".
What is Soleno Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Soleno Therapeutics?

Shares of Soleno Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Soleno Therapeutics's key executives?
Soleno Therapeutics's management team includes the following people:
- Dr. Anish Bhatnagar Pres, Chief Executive Officer, Chief Operating Officer & Director(age: 55, pay: $756,000)
- Mr. James H. MacKaness Chief Financial Officer(age: 61, pay: $198,990)
How many employees does Soleno Therapeutics have?

As Jul 2024, Soleno Therapeutics employs 33 workers.
When Soleno Therapeutics went public?

Soleno Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 13 Nov 2014.
What is Soleno Therapeutics's official website?

The official website for Soleno Therapeutics is soleno.life.
Where are Soleno Therapeutics's headquarters?

Soleno Therapeutics is headquartered at 203 Redwood Shores Parkway, Redwood City, CA.
How can i contact Soleno Therapeutics?

Soleno Therapeutics's mailing address is 203 Redwood Shores Parkway, Redwood City, CA and company can be reached via phone at +65 02138444.
What is Soleno Therapeutics stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Soleno Therapeutics in the last 12 months, the avarage price target is $67. The average price target represents a 0.28% change from the last price of $66.81.

Soleno Therapeutics, Inc.

soleno.life

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

+65 02138444

203 Redwood Shores Parkway
Redwood City, CA 94065

CIK: 0001484565
ISIN: US8342033094
CUSIP: 834203200